<p><strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 的股票在最近几周引起了轰动，达到了每股近 73 美元的新历史高点。然而，几天后，大部分涨幅又迅速回落，跌至每股低至 36 美元。现在，这正是大多数投资者会放弃并忘记他们最初为何购买该股票的时刻。</p>
<p>这没关系；在经历如此剧烈的下跌后，人们仍然相信公司的故事是人之常情。然而，市场向这些近期卖出股票的投资者展示了，仍然有一些合理的理由让投资者继续持有 Hims &amp; Hers 的股票，长期来看。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<p>这一假设可以通过股票从上周触及的低点反弹高达 24% 来得出，这给市场一个理由认为底部可能已经形成。</p>
<p>即使在这种潜在的复苏过程中，对于那些最近可能失去 Hims &amp; Hers 收益的投资者来说，情绪仍然偏向于报复，因此今天可能需要其他观点。假设这是在改善医疗行业的科技股中普遍存在的情绪，那么 <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> 有明确的路径可以像 Hims &amp; Hers 在回调前那样起飞。</p>
<h2><strong>价格走势更有利于 Clover 而非 Hims &amp; Hers 股票</strong></h2>
<p>如果价格走势和表现能反映市场对股票的整体感觉，投资者可以关注今天 Hims &amp; Hers 和 Clover 的交易情况。</p>
<p>考虑到 Clover 目前处于其 52 周高点的 82%，而 Hims &amp; Hers 仅为 62%，投资者可以在某种程度上假设市场现在更青睐 Clover。</p>
<p>但这种价格走势仅仅是开始，因为公司必须有其他基本因素来证明其当前的交易合理性。其中一个可能是华尔街对 Clover 每股收益（EPS）的当前预测，预计在 2025 年第二季度约为 0.03 美元。</p>
<p>这意味着与今天每股净亏损 0.02 美元相比，存在显著的跃升。考虑到股票价格通常由潜在的 EPS 增长驱动，这可能为 Clover 开辟了一条真正起飞的道路，类似于 Hims &amp; Hers 在今年早些时候的表现。</p>
<p>不过，还有其他基本利好因素在起作用，例如公司最新季度财报中看到的关键绩效指标（KPI）。第一个指标可以在平均医疗保险优势会员的年增长 30% 中看到。</p>
<p>基于会员的增长，投资者可以看到 Clover 报告的保险收入高达 3.307 亿美元，比去年同期增长 9.1%。</p>
<p>随着增长率朝这个方向发展，华尔街分析师对公司在未来几个月实现净盈利感到如此自信是有道理的。</p>
<h2><strong>Clover 股票还有多少上涨空间？</strong></h2>
<p>根据华尔街分析师的共识价格目标，Clover 股票今天的合理估值定为每股 5.0 美元。这不仅意味着新的 52 周高点，还意味着从当前交易价格上涨高达 26% 的潜力，为投资者在今天的布局中提供了足够的看涨空间。</p>
<p>考虑到华尔街对估值和 EPS 预测的看法，投资者看到先锋集团的配置者在 2025 年 2 月将其在 Clover 股票中的持股增加至 2.0% 也就不足为奇了。</p>
<p>从百分比上看，这可能听起来不算多。然而，这确实使他们的净头寸今天达到了 6170 万美元，或占公司 3.9% 的股份。</p>
<p>在这次近期购买中，还有一个重要因素需要考虑。这些配置者愿意为 Clover 股票支付高达 6.6 倍的市净率（P/B），高于医疗服务计划行业今天 4.9 倍的平均 P/B。</p>
<p>有人会认为这只股票相对于其同行来说价格昂贵。然而，经验丰富的交易者会提醒他们，市场总是愿意为他们认为有能力超越同行和整体市场的股票支付溢价，这在今天的 Clover 中似乎是一个合理的案例。</p>
<h2>你现在应该投资 1000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

三叶草健康

<p>Clover Health Investments Inc.（纳斯达克代码：CLOV）可能在 Hims & Hers Health Inc.（纽约证券交易所代码：HIMS）最近的反弹后迎来增长。Hims & Hers 的股价在经历了大幅下跌后，最近反弹了 24%，而 Clover 的交易价格为其 52 周高点的 82%。分析师预测，Clover 的每股收益将在 2025 年第二季度显著上升，这得益于医疗保险优势会员增长 30% 和保险收入增长 9.1%。在共识目标价为 5.00 美元的情况下，Clover 可能会有 26% 的上涨空间，尽管其市净率高于同行，但仍吸引了投资者的关注</p>

<p>Shares of <strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share. Now, this is where most investors would throw in the towel and forget why they bought the stock in the first place.</p>
<div class="lb-trans"><p><strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 的股票在最近几周引起了轰动，达到了每股近 73 美元的新历史高点。然而，几天后，大部分涨幅又迅速回落，跌至每股低至 36 美元。现在，这正是大多数投资者会放弃并忘记他们最初为何购买该股票的时刻。</p>
</div><p>This is alright; it’s human nature to still be convinced about a company’s story after such a steep decline. However, the market has shown these recent sellers that there are still some valid reasons for investors to keep hanging on to their shares of Hims &amp; Hers stock for the long haul.</p>
<div class="lb-trans"><p>这没关系；在经历如此剧烈的下跌后，人们仍然相信公司的故事是人之常情。然而，市场向这些近期卖出股票的投资者展示了，仍然有一些合理的理由让投资者继续持有 Hims &amp; Hers 的股票，长期来看。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><p>This assumption can be made by the way that the stock bounced back by as much as 24% from the lows hit last week, giving markets a reason to think that the bottom could be in now.</p>
<div class="lb-trans"><p>这一假设可以通过股票从上周触及的低点反弹高达 24% 来得出，这给市场一个理由认为底部可能已经形成。</p>
</div><p>Even with this potential recovery underway, the sentiment is still on the vengeful side of the spectrum for investors who potentially lost their gains in Hims &amp; Hers recently, so alternative views may be needed today. Assuming that this is the sentiment across the board in the technology stocks that improve the medical sector, there’s a clear path for <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> to take off just the way Hims &amp; Hers did before the pullback.</p>
<div class="lb-trans"><p>即使在这种潜在的复苏过程中，对于那些最近可能失去 Hims &amp; Hers 收益的投资者来说，情绪仍然偏向于报复，因此今天可能需要其他观点。假设这是在改善医疗行业的科技股中普遍存在的情绪，那么 <strong>Clover Health Investments Inc. NASDAQ: CLOV</strong> 有明确的路径可以像 Hims &amp; Hers 在回调前那样起飞。</p>
</div><h2><strong>Price Action Favors Clover Over Hims &amp; Hers Stock</strong></h2>
<div class="lb-trans"><h2><strong>价格走势更有利于 Clover 而非 Hims &amp; Hers 股票</strong></h2>
</div><p>If price action and performance are any indication of how the market overall feels about a stock, investors can look to where both Hims &amp; Hers and Clover are trading today.</p>
<div class="lb-trans"><p>如果价格走势和表现能反映市场对股票的整体感觉，投资者可以关注今天 Hims &amp; Hers 和 Clover 的交易情况。</p>
</div><p>Given that Clover is now sitting at 82% of its 52-week high, compared to only 62% for Hims &amp; Hers, investors could somewhat assume that the market now favors Clover.</p>
<div class="lb-trans"><p>考虑到 Clover 目前处于其 52 周高点的 82%，而 Hims &amp; Hers 仅为 62%，投资者可以在某种程度上假设市场现在更青睐 Clover。</p>
</div><p>But this price action is only the beginning, as there must be other fundamental factors at play for the company to justify its current trading. One could be the current Wall Street forecasts for earnings per share (EPS) in Clover, which hover around $0.03 for the second quarter of 2025.</p>
<div class="lb-trans"><p>但这种价格走势仅仅是开始，因为公司必须有其他基本因素来证明其当前的交易合理性。其中一个可能是华尔街对 Clover 每股收益（EPS）的当前预测，预计在 2025 年第二季度约为 0.03 美元。</p>
</div><p>This implies a significant jump from today’s net loss of $0.02 per share. Given that stock prices are typically driven by underlying EPS growth, this could open up a path for Clover to really take off in a similar manner to which Hims &amp; Hers did earlier this year.</p>
<div class="lb-trans"><p>这意味着与今天每股净亏损 0.02 美元相比，存在显著的跃升。考虑到股票价格通常由潜在的 EPS 增长驱动，这可能为 Clover 开辟了一条真正起飞的道路，类似于 Hims &amp; Hers 在今年早些时候的表现。</p>
</div><p>Other fundamental tailwinds are at play, though, such as the key performance indicators (KPIs) seen in the company’s latest quarterly earnings presentation. The first one of these indicators could be seen in the 30% annual growth in the average Medicare Advantage memberships.</p>
<div class="lb-trans"><p>不过，还有其他基本利好因素在起作用，例如公司最新季度财报中看到的关键绩效指标（KPI）。第一个指标可以在平均医疗保险优势会员的年增长 30% 中看到。</p>
</div><p>Based on this jump in memberships, investors can see how Clover reported up to $330.7 million of insurance revenue, a 9.1% growth rate from the same quarter in the previous year.</p>
<div class="lb-trans"><p>基于会员的增长，投资者可以看到 Clover 报告的保险收入高达 3.307 亿美元，比去年同期增长 9.1%。</p>
</div><p>With growth rates headed this way, it would make sense for Wall Street analysts to feel this confident about the company hitting net profitability in the coming months.</p>
<div class="lb-trans"><p>随着增长率朝这个方向发展，华尔街分析师对公司在未来几个月实现净盈利感到如此自信是有道理的。</p>
</div><h2><strong>But How Much Upside Is There For Clover Stock?</strong></h2>
<div class="lb-trans"><h2><strong>Clover 股票还有多少上涨空间？</strong></h2>
</div><p>Well, according to the consensus price target from Wall Street analysts, Clover stock’s fair valuation is set for $5.0 a share today. This calls for not only a new 52-week high but also a rally of up to 26% from where it trades today, proposing enough bullish upside for investors to consider in today’s setup.</p>
<div class="lb-trans"><p>根据华尔街分析师的共识价格目标，Clover 股票今天的合理估值定为每股 5.0 美元。这不仅意味着新的 52 周高点，还意味着从当前交易价格上涨高达 26% 的潜力，为投资者在今天的布局中提供了足够的看涨空间。</p>
</div><p>Considering this view on valuations and EPS forecasts from Wall Street, it shouldn’t be a surprise for investors to see allocators from the Vanguard Group boost their holdings in Clover stock by up to 2.0% as of February 2025.</p>
<div class="lb-trans"><p>考虑到华尔街对估值和 EPS 预测的看法，投资者看到先锋集团的配置者在 2025 年 2 月将其在 Clover 股票中的持股增加至 2.0% 也就不足为奇了。</p>
</div><p>This may not sound like much on a percentage basis. Still, it did bring their net position to a high of $61.7 million today, or 3.9% ownership in the company.</p>
<div class="lb-trans"><p>从百分比上看，这可能听起来不算多。然而，这确实使他们的净头寸今天达到了 6170 万美元，或占公司 3.9% 的股份。</p>
</div><p>Here’s an essential factor to consider in this recent purchase as well. These allocators were willing to pay up to 6.6x in price-to-book (P/B) for Clover stock today, a premium above the medical service plans industry’s 4.9x average P/B today.</p>
<div class="lb-trans"><p>在这次近期购买中，还有一个重要因素需要考虑。这些配置者愿意为 Clover 股票支付高达 6.6 倍的市净率（P/B），高于医疗服务计划行业今天 4.9 倍的平均 P/B。</p>
</div><p>Some would call this stock expensive next to its peers. However, seasoned traders would remind them that the market will always be ready to pay a premium for stocks that they believe have what it takes to outperform the peer group and the overall market, which seems to be a justifiable case in Clover today.</p>
<div class="lb-trans"><p>有人会认为这只股票相对于其同行来说价格昂贵。然而，经验丰富的交易者会提醒他们，市场总是愿意为他们认为有能力超越同行和整体市场的股票支付溢价，这在今天的 Clover 中似乎是一个合理的案例。</p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

错过了 Hims & Hers Health 的反弹？三叶草健康可能是下一个